GlassScriptPhysician profile
Michael G Teitel
NPI 1376509364
$11,683.15
in general payments reported to CMS, 2019-2025
29 companies · $882 in 2025
The $882 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,218 · 2020: $1,594 · 2021: $1,879 · 2022: $2,624 · 2023: $1,862 · 2024: $624 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,367.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,362.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,656.67 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $1,077.02 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $960.00 | 2019-2025 | Dupixent |
| Incyte Corporation | $754.12 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $475.96 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.19 | 2020-2022 | |
| Kaleo, INC. | $411.21 | 2019-2024 | Auvi-Q |
| Csl Behring | $340.36 | 2020-2023 | Haegarda, Hizentra |
| Teva Pharmaceuticals USA, INC. | $189.60 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $129.68 | 2022 | |
| Genentech USA, INC. | $90.29 | 2019-2020 | |
| Pfizer INC. | $85.01 | 2020-2021 | |
| Octapharma USA, INC. | $78.77 | 2019-2021 | |
| Amgen INC. | $76.44 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $70.79 | 2019 | |
| Abbvie INC. | $65.04 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.62 | 2020-2021 | |
| Optinose US, INC. | $48.56 | 2020 | |
| Advanced Respiratory, INC | $46.80 | 2019 | |
| Aimmune Therapeutics, INC. | $46.43 | 2022 | |
| Alk-Abello, INC | $36.09 | 2019 | |
| Grifols USA, LLC | $28.64 | 2022 | |
| Covis Pharma Gmbh | $24.86 | 2019 | |
| Pharming Healthcare, INC. | $23.30 | 2021 | |
| Mylan Specialty L.P. | $23.08 | 2021 | |
| Horizon Therapeutics Plc | $22.12 | 2023 | Actimmune |
| Eyevance Pharmaceuticals LLC | $21.93 | 2020 | |
| Phadia US INC. | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Teitel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.